MHRA approves Seagen’s oral HER2 drug Tukysa


22 February 2021 - The UK drugs regulator has approved Seagen’s Tukysa as a third-line treatment for HER2 positive breast cancer, shortly after it was given a green light by the European Commission.

Tukysa (tucatinib) – an orally active HER2 inhibitor – can be used in combination with anti-HER2 antibody trastuzumab and chemotherapy capecitabine in patients treated with two prior anti-HER2 regimens, according to the MHRA.

Read Pharmaphorum article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Outcome , England , Medicine